GlaxoSmithKline Whistleblower Case

An enormous $1 billion in criminal fines and $2 billion in civil fines were levied against GlaxoSmithKline, a major pharmaceutical corporation, as a result of the illegal promotion of prescription drugs, in one of the most significant whistleblower cases in the history of the pharmaceutical industry. However, how did this massive probe come to be?

Learn more about the GlaxoSmithKline Whistleblower case:

• The bravery of two whistleblowers who initially voiced their concerns internally in 2001, only to be overlooked by GlaxoSmithKline. Their persistence led them to federal authorities in 2003, igniting a lengthy and intricate 9+ year investigation.
• How this case serves as a stark reminder of the complexities of governmental investigations and their time-consuming nature.
• A critical lesson for corporations: with only 10% of allegations resulting in inquiries, there are missed opportunities for companies to address and resolve issues internally.

This case serves as a reminder of the value of corporate ethics and internal grievance procedures, as well as the tremendous influence and breadth of whistleblowers in exposing systemic corporate wrongdoing.

Tune in for a thorough examination of the GSK Whistleblower Case and its larger consequences.